StromaForte stem cell injection compared with hyaluronic acid for knee osteoarthritis
Compares StromaForte injections with hyaluronic acid in adults with knee osteoarthritis.
Key facts
- Who runs it
- Cellcolabs Clinical SPV Limited
- Where
- United Arab Emirates1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- An Open-Label, Double-Treatment Group Study to Evaluate the Efficacy and Safety of Human Allogeneic Bone-Marrow- Derived Mesenchymal Stromal Cell Product StromaForte Compared With Hyaluronic Acid for the Treatment of Knee Osteoarthritis
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 140 people, planned
- Started
- 27 Apr 2026
- Expected to end
- 27 Sept 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Mesenchymal Stem Cells (MSC)
- Hyaluronic Acid (HA)
- Record updated
- 21 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with knee osteoarthritis (wear-and-tear arthritis) and knee pain during activity. It compares StromaForte cell injections with hyaluronic acid injections.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Knee osteoarthritis Grade I to IV on the Kellgren-Lawrence X-ray scale, confirmed by images no older than three months. Pain during activity of 40 or more on the Visual Analogue Scale (VAS). BMI between 18.5 and 35.0 kg/m2.
- Earlier treatment
- No corticosteroid injection into any joint or the body within 3 months before screening. No stem cell therapy within the previous 12 months. No other trial drug within 30 days.
Main reasons for not taking part
- Unstable knee from a complete ligament tear, or leg misalignment over 5 degrees.
- Partial meniscus removal less than 9 months ago, or planned leg surgery within 12 months.
- Weakened immune system from illness or medicines, or infection such as HIV, hepatitis or syphilis.
- Cancer in the past 2.5 years, except early cancers removed by local surgery.
- Pregnancy or breastfeeding, or a blood clot in the lungs or legs within the past 4 months.
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Willing and able to provide written informed consent and comply with all procedures required by the protocol
- Aged ≥ 18 years at the time of signing the informed consent form
- Diagnosed with knee osteoarthritis (OA) based on the criteria established by the American College of Rheumatology, confirmed through radiological images no older than three months
- Grade I to IV osteoarthritis on the Kellgren-Lawrence radiological classification scale
- Joint pain during activity as assessed by the Visual Analogue Scale (VAS) of ≥ 40 at the time of screening
- Body Mass Index (BMI) between ≥ 18.5 to ≤ 35.0 kg/m2
Who cannot take part
- Systemic or intra-articular injection of corticosteroids in any joint within 3 months before screening
- Planned orthopaedic surgery on lower limbs within the next 12 months
- Participation in another clinical trial including treatment with a different investigational product within 30 days prior to inclusion in this study
- Unwilling or for medical reason not recommended to pause anticoagulant medications prior to procedure, as judged by prescribing doctor
- Recipient of any stem cell therapy within the previous 12 months
- History of subtotal medial or lateral meniscectomy performed less than 9 months ago
- History of septic arthritis in the targeted knee
- History of infectious or inflammatory joint disorders or suspected infective or inflammatory joint disease
- Immunosuppression due to illness or medication including but not limited to high dose corticosteroids, calcineurin inhibitors, anti-TNF, anti-IL-6, anti-p40, biologics and prednisone and/or equivalent over 5 mg/day
- Active or suspected infection
- History of malignancy in the past 2.5 years, except in-situ cancers treated by local excision with curative intent
- Severe bleeding diathesis
- Known diagnosis of HIV-1, HIV-2, Hepatitis A, Hepatitis B, Hepatitis C, HTLV-I/II, or Syphilis, or other acute or chronic infectious disease
- Pulmonary embolism, deep vein thrombosis or other serious embolic disease within the past 4 months
- Known allergies or hypersensitivity to DMSO, human serum albumin, heparin or PlasmaLyte
- History or current evidence of any condition, therapy, laboratory abn ormality, or other circumstance that might confound the results of the study or interfere with the study participant's participation for the full duration of the study
- Unwilling or unable to perform any of the assessments required by the protocol
- Mechanically unstable knee due to the presence of a complete anterior cruciate ligament, posterior cruciate ligament, medial collateral ligament and/or posterolateral corner tear
- Varus or valgus malalignment >5 degrees as measured by 4-foot standing antero-posterior radiographs
- Pregnancy or breastfeeding
- Cognitive or language barriers that prohibit obtaining informed consent, questionnaires or any study elements
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
StromaForte injection for knee OA
The 2 groups in the trial
- StromaForte- Mesenchymal Stem cellsTreatment being tested
Human Allogenic Bone marrow derived Mesenchymal Stem cells
Treatment: Mesenchymal Stem Cells (MSC)
- Hyaluronic AcidExisting treatment, for comparison
Treatment: Hyaluronic Acid (HA)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-Label, Double-Treatment Group Study to Evaluate the Efficacy and Safety of Human Allogeneic Bone-Marrow- Derived Mesenchymal Stromal Cell Product StromaForte Compared With Hyaluronic Acid for the Treatment of Knee Osteoarthritis
- Plain-language title
- StromaForte stem cell injection compared with hyaluronic acid for knee osteoarthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 21 April 2026